Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+antibodies

25 Results

Sort By:

Value Proposition· Target associated with viral load reduction identified from a large pool of study participants who had low level viremia· Potential to reduce disease severity in at-risk populations· Proactive approach to lower viral load in individuals who could become infected Unmet NeedHuman immunodeficiency virus (HIV) impacts millions...

Published: 5/10/2024 | Inventor(s): Susan Eshleman, Harry Larman, Kai Kammers, Oliver Laeyendecker, Wendy Grant-McAuley

Keywords(s):

Category(s): Clinical and Disease Specializations > Infectious Diseases > HIV, Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Recombinant anti-PAD4 antibodies as a treatment for lung fibrosis

Value PropositionSelective monoclonal antibody therapy to treat lung fibrosis.Directly targets immune cells to promote a pro-inflammatory pathway that reduces fibrosis.High serum levels are associated with less severe lung disease, decreased fibrosis, and improved survival in a subset of rheumatoid arthritis patients.Broadly applicable to other diseases...

Published: 5/10/2024 | Inventor(s): Erika Darrah, Felipe Andrade, Kristen Demoruelle, Elizabeth Redente

Keywords(s):

Category(s): Clinical and Disease Specializations > Fibrosis, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications, Technology Classifications > Therapeutic Modalities

Polymers for Binding-Triggered Antibody Precipitation and Purification

Value PropositionResults in >97% precipitation yield, >88% elution yield of mAbsSimplified molecular design compared to elastin-like polypeptide (ELP)-based materialsDoes not need additional salt to achieve mAb precipitation and recoveryTechnology DescriptionResearchers at Johns Hopkins have developed a peptide-based platform technology using...

Published: 5/10/2024 | Inventor(s): Honggang Cui, Yi Li, David Stern, XuanKuo Xu, Lye Lin Lock, Jason Mills, Sanchayita Ghose, Zheng Jian Li

Keywords(s):

Category(s): Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Research Tools, Technology Classifications > Research Tools > Antibodies, Technology Classifications > Research Tools > Research Antibodies, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Antibody for DNA Degradation

Value Proposition· Autoantibody that promotes DNA degradation to diminish inflammation· Enhances endonuclease DNase1L3 activity· Avoids kidney-mediated inflammatory response Unmet Need· Extracellular DNA, also called cell-free DNA, released from dying cells or activated immune cells can be recognized by the immune system...

Published: 5/10/2024 | Inventor(s): Felipe Andrade, Jose de Jesus Eduardo Gomez-Bañuelos

Keywords(s):

Category(s): Clinical and Disease Specializations > Genetic Diseases > Cystic Fibrosis, Clinical and Disease Specializations > Gastroenterology > Inflammatory Bowel Disease, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies, Clinical and Disease Specializations > Inflammation > Arthritis

Engineered Cytokine-antibody Fusion for Targeted Expansion of Immune Effector Cells

Unmet NeedGlobal revenue from the cytokine therapeutics market was valued at approximately $16.5 billion in 2018, and cytokine immunotherapy is a promising field of anti-cancer treatments for a broad range of cancer types. In particular, interleukin-2 (IL-2) therapy is shown to stimulate anti-cancer immunity. However, IL-2 activates contradictory immune...

Published: 5/9/2024 | Inventor(s): Jamie Spangler, Jakub Tomala, Michael Leff, Seth Ludwig, Elissa Leonard, Marek Kovar, Jirina Kovarova

Keywords(s): Biologics, Cancers, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Antibodies, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Biologics

Predicting infection severity and antibody treatment

Unmet NeedThe spectrum of COVID-19 symptomatic infection ranges from mild to critical. Severe illness can occur in healthy individuals of any age, but it predominantly occurs in adults with advanced age or certain underlying medical comorbidities (e.g. cardiovascular disease, diabetes, hypertension, chronic lung disease, obesity). Some prediction tools...

Published: 5/10/2024 | Inventor(s): Roger Johns, Qing Lin, John Skinner

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Antibodies

Rapid Assay for Carcinoma Stem Cells

Unmet NeedWhile cancer therapeutics have drastically improved patient outcomes in numerous indications, novel methods to prevent cancer metastasis and recurrence are needed. Cancer stem cells (CSCs) are a unique subpopulation of a tumor that are more oncogenic and slow-growing than other cancer cells within the tumor. CSCs make up approximately .1-10%...

Published: 5/9/2024 | Inventor(s): William Matsui, Xiaobing He, David Berman

Keywords(s): Antibodies, Biologics, Bladder Cancer, Cancers, Disease Indication, Immunotherapy, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Urology, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Bladder Cancer

Screening Method to Identify Scleroderma Immune Responses with Anti-cancer Activity, and Induction of such Immune Responses for Cancer Therapy

Unmet NeedEpidemiological studies have shown that patients with scleroderma, a type of autoimmune rheumatic disease affecting the skin and connective tissues, have an increased risk of developing cancer relative to the general population. The exact etiology of scleroderma is still unknown. The Scleroderma Foundation estimates about 100,000 to 300,000...

Published: 5/9/2024 | Inventor(s): Ami Shah, Livia Casciola-Rosen, Antony Rosen, Takeru Igusa, Marikki Laiho

Keywords(s): Antibodies, Autoimmune Diseases, Biologics, Biomarker, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Inflammatory Disorders, Risk Stratification, Scleroderma, Skin Disorders, Skin Fibrosis, Therapeutic Matter, Therapeutic Substance, Therapeutics

Human Stem Cells and Monoclonal Antibodies (MY-10)

Human Stem Cells and Monoclonal Antibodies (MY-10) Case Number C02182 ABSTRACT Monoclonal antibodies that recognize a stage-specific antigen on immature human marrow cells. These antibodies are useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation. Cell suspensions containing...

Published: 5/9/2024 | Inventor(s): Curt Civin

Keywords(s): Antibodies, Biologics, Bone Marrow, Bone Marrow Transplant, Cell Therapy, Disease Indication, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Transplants

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Transplantation, Clinical and Disease Specializations > Transplantation > Bone Marrow Transplant

Manipulation of Regulatory T Cell and DC Function by Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists

Unmet NeedThe recent breakthroughs in immuno-oncology have changed the way that researchers think about treating autoimmune diseases and cancer by modulating the immune system. Regulatory T cells (Treg) limit autoimmunity but also attenuate the potency of antitumor immunity. Enhancement of Treg function could treat autoimmune diseases while the inhibition...

Published: 5/9/2024 | Inventor(s): Drew Pardoll, Joseph Barbi, Fan Pan, Hong Yu, Ching-Tai Huang, Xiaoyu Pan, Charles Drake, Jonathan Powell

Keywords(s): Antibodies, Biologics, Cancers, Disease Indication, Immunotherapy, Infectious Diseases, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics

1 2 3